Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Pharmacists play a critical but often underrecognized role in protecting brain health and slowing cognitive decline. While most people think of pharmacists as pill dispensers, they are actually medication experts positioned at the frontline of dementia prevention and treatment. With 7.4 million Americans age 65 and older currently living with Alzheimer’s disease, and brain changes now detectable before symptoms appear, pharmacists have unprecedented opportunities to intervene early—through medication review, disease-modifying therapy support, and personalized counseling that can meaningfully impact cognitive outcomes. Consider a 68-year-old patient who visits her local pharmacy to refill her allergy and sleep medications. A knowledgeable pharmacist might notice that her current medications contain anticholinergic properties, a class of drugs linked to accelerated cognitive decline.
That single conversation—and the subsequent medication adjustment—could reduce her dementia risk more effectively than any supplement or wellness trend. This is how pharmacists protect brain health: by catching what others miss, understanding how individual medications affect cognition, and guiding patients toward safer alternatives. The window of opportunity for intervention is expanding rapidly. Pharmacists are now positioned to support patients taking lecanemab and donanemab, FDA-approved disease-modifying therapies for mild cognitive impairment and mild dementia. Some formulations can eventually be dispensed directly from pharmacies, making pharmacists central to modern Alzheimer’s care. But their role extends far beyond dispensing these newer drugs—it encompasses medication safety, prevention strategies, and the kind of personalized health guidance that makes a real difference in brain health outcomes.
Table of Contents
- How Pharmacists Identify Medications That Harm Cognition
- Supporting Disease-Modifying Therapies and Early Detection
- Building Cognitive Reserve—The Prevention Strategy Everyone Can Access
- Medication Therapy Management and Personalized Drug Safety
- Long COVID and Emerging Brain Health Concerns
- Fall Prevention and Hospitalization-Related Cognitive Decline
- The Expanding Role of Pharmacists in Dementia Care
- Conclusion
How Pharmacists Identify Medications That Harm Cognition
One of the most practical ways pharmacists protect brain health is by reviewing medications that increase dementia risk. anticholinergic medications—commonly prescribed for allergies, sleep problems, depression, and overactive bladder—are among the most concerning. A landmark study found that older adults who took anticholinergic medications with cumulative exposure exceeding 1,095 standardized daily doses within a 10-year period had a 50% higher odds of developing dementia, even after accounting for other risk factors. The problem is disturbingly common. Research showed that 57% of patients taking anticholinergic medications were prescribed at twice the recommended dosage for older adults, and 18% received at least four times the recommended dose.
These are not rare exceptions—they represent systematic overmedication patterns across the country. A pharmacist reviewing a patient’s medication list can catch these discrepancies, counsel the patient on risks, and work with the prescriber to switch to safer alternatives. Sometimes the solution is simple: choosing a non-anticholinergic antihistamine, or using melatonin instead of a sedating medication with cognitive side effects. This kind of medication review isn’t just theoretical. When a pharmacist intervenes—perhaps suggesting a different antidepressant with fewer cognitive effects, or helping a patient taper off a medication no longer needed—they’re directly reducing that person’s dementia risk. This is one of the most impactful ways pharmacists work, yet it often happens quietly, without fanfare or recognition.
Supporting Disease-Modifying Therapies and Early Detection
For decades, Alzheimer’s disease was essentially untreatable once symptoms appeared. The new frontier is catching the disease before symptoms emerge. Brain changes can now be detected through advanced imaging and biomarker testing, creating a therapeutic window where disease-modifying treatments can slow cognitive decline. Pharmacists are uniquely positioned to support patients on these new medications and help maximize their benefit. Lecanemab and donanemab are the two FDA-approved disease-modifying therapies currently available for mild cognitive impairment and mild dementia. Lecanemab, administered intravenously, targets amyloid-beta, a protein that accumulates in Alzheimer’s disease.
A newer subcutaneous formulation has been approved for maintenance dosing and could soon be dispensed directly from community pharmacies—fundamentally changing how patients access this therapy. Donanemab offers another mechanism: a different biomarker target that may appeal to certain patients or offer advantages for specific populations. However, these medications come with important limitations. They slow cognitive decline but do not stop it or reverse existing damage. They require regular dosing and monitoring for amyloid-related imaging abnormalities (ARIA), a potentially serious side effect that requires MRI surveillance. Pharmacists will be essential in monitoring for adverse effects, ensuring adherence, and educating patients about realistic expectations. The patient who receives lecanemab expecting a cure will be disappointed; the patient who understands it as a tool to buy time while building cognitive reserve has a more realistic and sustainable approach.
Building Cognitive Reserve—The Prevention Strategy Everyone Can Access
While disease-modifying drugs represent breakthrough treatments for diagnosed disease, the most practical and accessible way to protect brain health is still building cognitive reserve. This is the brain’s capacity to resist age-related decline through education, cognitive stimulation, physical exercise, social engagement, and diet. A remarkable finding from recent research is that cognitive reserve can delay the onset of dementia symptoms by up to 10 years—a more dramatic difference than any current medication offers. A 70-year-old patient who reads regularly, maintains close friendships, exercises three times weekly, and follows a Mediterranean-style diet is building a powerful defense against cognitive decline. If Alzheimer’s pathology does accumulate in her brain, that cognitive reserve means her symptoms might not appear until age 85 instead of 75.
For many people, that’s the difference between living independently through the end of life or spending years in cognitive decline. Pharmacists can reinforce these prevention strategies in every patient interaction, emphasizing that medication management is just one pillar of brain health. The limitation here is obvious: cognitive reserve requires sustained effort and active engagement. It cannot be passively received like a medication. For patients with limited education, mobility challenges, or isolation, building cognitive reserve may be more difficult. This is where the pharmacist’s broader role becomes essential—connecting patients with community resources, recommending physical activity, discussing nutritional strategies, and acknowledging the real barriers people face to healthy brain aging.
Medication Therapy Management and Personalized Drug Safety
Medication therapy management, or MTM, is a service pharmacists provide to ensure each medication a patient takes is the most effective and safest option for that individual’s situation. This goes beyond checking for drug interactions; it involves reviewing whether a patient actually needs all their medications, whether the dosages are appropriate for their age and kidney function, and whether there are less risky alternatives available. For someone on multiple medications, the interaction effects can be compounded. A patient on a statin, blood pressure medication, anticholinergic sleep aid, and pain medication is exposed not just to each drug’s individual effects, but to their combined impact on cognition and balance.
An MTM review conducted by a pharmacist might identify that the sleep aid is causing daytime grogginess, increasing fall risk, while also contributing to cognitive decline. Switching to a safer sleep strategy—perhaps sleep hygiene improvement or a different medication class—could improve cognition, reduce falls, and lower the dementia risk. Cognitive pharmaceutical services represent an emerging specialization where pharmacists apply deep knowledge of drug effects on the brain to prevent medication-related cognitive problems. This is particularly valuable during hospitalization, where delirium—an acute state of confusion and cognitive impairment—is common and often caused by medication interactions or inappropriate dosing in older patients. A pharmacist’s intervention during a hospital stay can literally prevent permanent cognitive damage that might otherwise be attributed to “normal aging.”.
Long COVID and Emerging Brain Health Concerns
A newer concern for brain health that pharmacists should recognize is long COVID—the condition affecting millions who experienced lasting neurological changes after COVID-19 infection. Even in people who recovered from acute infection, COVID-19 can affect brain tissue microstructure and neurochemical levels. Symptoms like brain fog, memory problems, slowed thinking, and persistent fatigue may indicate long COVID rather than early dementia or normal aging.
Patients experiencing these symptoms may interpret them as signs of cognitive decline and may actually develop anxiety about dementia risk, compounding their distress. A pharmacist who recognizes the long COVID pattern can provide crucial reassurance and guidance, including discussion of whether certain medications might help manage symptoms or if others might be exacerbating cognitive complaints. This represents a significant gap in many patients’ care, since long COVID symptoms are often dismissed or attributed to mental health conditions rather than recognized as post-viral neurological effects.
Fall Prevention and Hospitalization-Related Cognitive Decline
A less obvious but significant way pharmacists protect brain health is by preventing falls and complications during hospitalization—both of which can trigger permanent cognitive decline in older adults. Medications that affect balance, blood pressure, or alertness increase fall risk, and pharmacists reviewing medication lists can identify these hazards and suggest alternatives or dosage adjustments.
During hospitalization, older patients are particularly vulnerable to delirium and cognitive impairment, often triggered by medication changes, interactions, or inappropriate dosing for someone with reduced kidney function. A pharmacist monitoring the hospital stay can prevent this decline by catching medication errors, questioning potentially harmful additions to the regimen, and recommending early discontinuation of medications no longer needed. This preventive role may seem less dramatic than prescribing disease-modifying therapies, but it protects cognition in real patients facing real vulnerability.
The Expanding Role of Pharmacists in Dementia Care
The role of pharmacists in dementia prevention and treatment is expanding rapidly. With subcutaneous lecanemab approaching approval for community pharmacy dispensing, and with growing recognition of pharmacists’ expertise in medication safety and cognitive health, the profession is positioning itself at the center of brain health care. This represents a significant shift from the traditional pharmacy model, where the pharmacist’s role was largely limited to filling prescriptions.
Looking forward, as 55 million people worldwide live with dementia and global dementia care costs exceed $1.3 trillion annually—projected to reach $2.8 trillion by 2030—the economic and human case for early intervention becomes increasingly urgent. Pharmacists, who have direct access to patients and credibility as medication experts, are uniquely positioned to identify at-risk individuals, counsel on prevention, support disease-modifying therapies, and monitor for medication-related cognitive harm. This role will only become more central as brain health emerges as a leading health priority for aging populations.
Conclusion
Pharmacists protect brain health through multiple pathways: identifying and eliminating medications that harm cognition, supporting patients on disease-modifying therapies, counseling on prevention strategies, and preventing the medication-related complications that can trigger cognitive decline. Their work is practical, evidence-based, and immediately actionable in every community pharmacy. A single conversation with a knowledgeable pharmacist about medication safety or cognitive prevention can meaningfully shift a patient’s trajectory toward healthier brain aging.
If you are concerned about your brain health or cognitive decline, a medication review with your pharmacist is one of the most valuable conversations you can have. Bring a list of all your medications and supplements, be honest about your memory concerns and symptoms, and ask specifically whether any of your current medications might be affecting your cognition. Your pharmacist’s expertise in this area may be the overlooked piece of brain health protection you’ve been missing.
You Might Also Like
- Why Processed Diets Are Studied in Brain Health
- How Food Quality Connects to Brain and Heart Health
- Why Group Fitness May Help Brain and Social Health
Related reading
- how Caregivers Can Improve Diet Without Perfection
- what Food Habits May Support Healthy Aging
- can Dementia Be Linked to Kidney Disease
- why Chronic Illnesses Affect Cognitive Health
- how Organ Health Shapes Brain Function
For more on this topic, see Alzheimer’s Association — clinical trials.
